<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <p content-type="self-citation">
  <mixed-citation publication-type="journal" id="jns12267-cit-9001">
   <string-name>
    <surname>Cornblath</surname>
    <given-names>DR</given-names>
   </string-name>, 
   <string-name>
    <surname>Hartung</surname>
    <given-names>H‐P</given-names>
   </string-name>, 
   <string-name>
    <surname>Katzberg</surname>
    <given-names>HD</given-names>
   </string-name>, 
   <string-name>
    <surname>Merkies</surname>
    <given-names>ISJ</given-names>
   </string-name>, 
   <string-name>
    <surname>van Doorn</surname>
    <given-names>PA</given-names>
   </string-name>. 
   <article-title>A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol</article-title>. 
   <source xml:lang="en">J Peripher Nerv Syst</source>. 
   <year>2018</year>;
   <volume>23</volume>:
   <fpage>108</fpage>–
   <lpage>114</lpage>. 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jns.12267" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1111/jns.12267</ext-link>
   <pub-id pub-id-type="pmid">29603842</pub-id>
  </mixed-citation>
 </p>
 <fn-group id="jns12267-ntgp-0101">
  <fn id="jns12267-note-0101">
   <p>
    <bold>Funding information</bold> Octapharma Pharmazeutika Produktionsgesm. b.H., Vienna, Austria
   </p>
  </fn>
 </fn-group>
</notes>
